D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
RXRX holding history
Recursion Pharmaceuticals, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
RXRX overviewAll 13F holders of RXRXFull Q2 2026 holdings
- Shares (Q2 2026)
- 37,914
- Value
- $139.1K
- % of portfolio
- <0.1%
- Quarters held
- 10
- Since Q1 2023
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 37,914 | $139.1K | <0.1% | −8,094−17.6% | Reduced | Holders |
| Q1 2026 | 46,008 | $141.2K | <0.1% | −43,536−48.6% | Reduced | Holders |
| Q4 2025 | 89,544 | $366.2K | <0.1% | +89,544 | New | Holders |
| Q3 2025 | 0 | $0 | 0.0% | −633,403−100.0% | Sold out | Holders |
| Q2 2025 | 633,403 | $3.21M | <0.1% | +572,497+940.0% | Added | Holders |
| Q1 2025 | 60,906 | $322.2K | <0.1% | +60,906 | New | Holders |
| Q2 2024 | 0 | $0 | 0.0% | −61,963−100.0% | Sold out | Holders |
| Q1 2024 | 61,963 | $617.8K | <0.1% | +46,904+311.5% | Added | Holders |
| Q4 2023 | 15,059 | $148.5K | <0.1% | −8,648−36.5% | Reduced | Holders |
| Q3 2023 | 23,707 | $181.4K | <0.1% | +11,862+100.1% | Added | Holders |
| Q2 2023 | 11,845 | $88.5K | <0.1% | −191,053−94.2% | Reduced | Holders |
| Q1 2023 | 202,898 | $1.35M | <0.1% | +202,898 | New | Holders |